CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.

Zibo ChenTao YuanFangjie YanSong YeQin XieBo ZhangNengmin LinQiaojun HeBo YangHong Zhu

Published in: BMC cancer (2022)

Overall, this study not only favors the development of this novel multi-kinase inhibitor CT-707 as a therapeutic agent against HCC, but also provides a potential strategy to overcome the hypoxia-mediated resistance to sorafenib in HCC patients.

Keyphrases

end stage renal disease
computed tomography
image quality
ejection fraction
endothelial cells
dual energy
contrast enhanced
chronic kidney disease
peritoneal dialysis
signaling pathway
magnetic resonance imaging
positron emission tomography
risk assessment
patient reported outcomes
magnetic resonance